Core Insights - INmune Bio is a clinical stage biotechnology company focused on developing therapies for neuroinflammation in neurodegenerative diseases, with its lead program XPro1595 being a first-in-class selective soluble TNF inhibitor [1] Group 1: Clinical Development - The objective of the recent webinar was to demonstrate how the clinical results from the Phase II MINDFuL trial will inform the registration program for XPro1595 [2] - A productive end of Phase II meeting with the FDA confirmed alignment on the core elements of the Phase III registration program [2] Group 2: Trial Design and Outcomes - The MINDFuL trial was a strategic proof-of-concept study designed to address two critical variables: biologic signal and patient selection in Alzheimer's disease [3] - The trial aimed to determine if XPro1595 shows biologic activity in patients with Alzheimer's disease and inflammation biomarkers, and whether the right patient population for a registration trial could be identified [3] - Results indicated that XPro1595 demonstrated biologic activity and validated a precision medicine roadmap for the Phase III registration program [3]

Core Insights - The FDA has provided regulatory clarity on INmune Bio's integrated Phase 2b/3 clinical development strategy for XPro1595 in early Alzheimer's Disease, confirming CDR-SB as the sole primary endpoint for registrational development [1][2][5] FDA Alignment Highlights - The FDA's feedback validates the enrichment-led design and primary endpoint, supporting the scientific and clinical strategy of the company [2][5] - The Phase 2b study will include approximately 300 participants over a nine-month evaluation period, utilizing the Early Mild Alzheimer's Cognitive Composite (EMACC) and plasma p-tau-217 as key measures [4][5] - CDR-SB will serve as the sole primary efficacy endpoint for the Phase 3 segment, aligning with its established role in Alzheimer's therapies [5][6] Integrated Phase 2b/3 Framework - The FDA indicated no objection to the integrated Phase 2b/3 design under a single master protocol, with the full program expected to enroll around 1,000 participants [5] - The Phase 3 portion will evaluate XPro1595 over an 18-month period [5] - An exploratory cohort of non-enriched early Alzheimer's patients will be included to assess broader effects, comprising approximately 20% of total enrollment [5] XPro™ Overview - XPro™ is a next-generation TNF inhibitor that selectively neutralizes soluble TNF, potentially reducing neuroinflammation and improving cognitive function in neurological diseases [8] Company Background - INmune Bio Inc. is a late-stage clinical biotechnology company focused on developing treatments targeting the innate immune system, with three product platforms including XPro™ [9]

Core Insights - INmune Bio, Inc. announced new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595 in early Alzheimer's disease patients with elevated neuroinflammation, to be presented at the 18th Clinical Trials on Alzheimer's Disease conference [1][2] Group 1: Clinical Trial Results - The new analyses support XPro1595's mechanism of selectively neutralizing soluble TNF (sTNF), validating the strategy of targeting inflammation-driven Alzheimer's disease, which represents a significant unmet need [2][9] - PerpPD+ MRI imaging analysis indicated a trend towards slowed neurodegeneration progression in patients receiving XPro1595, particularly in those with early Alzheimer's and high inflammatory burden [3][8] - Findings suggest reduced cortical disarray, an imaging hallmark of neurodegeneration, reinforcing previously reported improvements across biological, cognitive, and neuropsychiatric endpoints [4][5] Group 2: Future Developments - Additional MRI analyses from the MINDFuL trial are ongoing and will provide a broader understanding of XPro1595's impact on gray- and white-matter integrity in Alzheimer's patients [7] - The totality of data generated to date positions XPro1595 as a promising first-in-class disease-modifying therapy for Alzheimer's patients with elevated neuroinflammation, a population with limited treatment options [9][10] Group 3: Company Overview - INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments targeting innate immune dysfunction to combat diseases [11] - The company's pipeline includes XPro1595, an inhibitor of soluble TNF that aims to restore healthy innate immune function without the immunosuppressive effects of traditional TNF inhibitors [10]

Core Insights - INmune Bio, Inc. is set to present two studies at the 18th Clinical Trials on Alzheimer's Disease conference in San Diego from December 1-4, 2025 [1][2] Presentations - The first presentation will focus on XPro1595, a selective soluble TNF neutralizer, in early Alzheimer's disease with inflammation, showcasing results from the Phase 2 MINDFuL trial [2] - The second presentation will validate the Early Mild Alzheimer's Cognitive Composite (EMACC) through associations with blood-based biomarkers of Alzheimer's disease [2] Company Overview - INmune Bio Inc. is a clinical-stage biotechnology company specializing in treatments targeting immunology and inflammation [3] - The company has three product platforms: - The Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, which selectively neutralizes soluble TNF [3] - CORDStrom™, a proprietary platform utilizing human umbilical cord-derived mesenchymal stromal cells, which recently completed a trial in recessive dystrophic epidermolysis bullosa [3] - INKmune®, designed to prime natural killer cells to eliminate minimal residual disease in cancer patients, currently in trials for metastatic castration-resistant prostate cancer [3]

Core Viewpoint - Former hedge fund manager Martin Shkreli has warned of a potential 90% drop in shares of Inmune Bio Inc., a biotech startup focused on using the immune system to combat cancers, following a recent surge in its stock price [1][2]. Group 1: Stock Performance and Predictions - Shkreli predicts that Inmune Bio's stock could fall to $0.50, representing a 90.61% decline from its closing price of $5.33 on the previous Friday [2]. - The company's shares had recently surged by 44% due to investor enthusiasm surrounding its neuroinflammation candidate, XPro1595, which targets Alzheimer's disease and other central nervous system disorders [2]. Group 2: Critique of Inmune Bio - Shkreli has expressed concerns regarding the lack of robust Phase 1 trial data and the absence of peer-reviewed publications supporting the efficacy of the candidate [4]. - He criticized the study design for not including a placebo arm, which complicates the assessment of whether observed improvements are due to the drug or a placebo effect [4]. - BMF Reports, an activist short-seller, has echoed Shkreli's concerns, highlighting flawed science, questionable trial designs, and accounting improprieties, including payments to "ghost consultants" [5]. Group 3: Market Reaction - Following Shkreli's warning, Inmune Bio's shares fell by 15.13% on Friday and continued to decline by 16.32% in after-hours trading [7].

Company Overview - INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments targeting the innate immune system to combat diseases, particularly Alzheimer's Disease [3] - The company operates three product platforms: Dominant-Negative Tumor Necrosis Factor (DN-TNF), Natural Killer Cell Priming Platform, and CORDStrom™ [3] - DN-TNF product candidates are in clinical trials for Mild Alzheimer's disease, Mild Cognitive Impairment, and treatment-resistant depression [3] - INKmune® is designed to prime NK cells to eliminate minimal residual disease in cancer patients and is currently in trials for metastatic castration-resistant prostate cancer [3] - CORDStrom™ is a proprietary platform that recently completed a trial in recessive dystrophic epidermolysis bullosa [3] Upcoming Events - The company will host a conference call on May 8th, 2025, at 4:30 PM EDT to discuss the results for the quarter ended March 31, 2025, and provide a corporate update [1][2] - Participants can join the call by dialing in 5 to 10 minutes before the start time [2] Financial Information - The company is publicly traded on NASDAQ under the ticker INMB [3]